^
Association details:
| Biomarker: | MLL rearrangement + FLT3 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | FHD-286 (SMARCA2 inhibitor, SMARCA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4160 Notable Efficacy of Co-Treatment with FHD-286, a Dual BRG1/BRM ATP-Ase Inhibitor, and Menin or BET Inhibitor, Decitabine or Venetoclax Against AML with MLL-r or Mutant NPM1
Published date:
11/02/2023
Excerpt:
In a PD xenograft (PDX) model of MLL1r AML with FLT3 mutation, monotherapy with FHD-286 (oral gavage) for 4 to 6-weeks was significantly effective in reducing AML burden and improving overall survival.
